Quotient Sciences, the Ruddington drug development services organisation, has bought Pharmaterials, a contract development and manufacturing organisation (CDMO) based in Reading, for an undisclosed sum.
The deal follows the acquisitions of SeaView Research and QS Pharma in February 2017.
Pharmaterials has a significant track record in supporting the development of small molecule drug products for oral and inhaled delivery. The business was founded in 2000 and is located in a 48,000 sq ft facility.
Mark Egerton, chief executive, Quotient Sciences, said: “The acquisition of Pharmaterials strengthens Quotient’s service portfolio from preclinical formulation development through to commercial manufacturing. The addition expands Quotient’s global CDMO services with added capacity and capabilities to better serve our clients’ needs.”
To find out more about Quotient Sciences, please click here to go to the website.
